By Lynda Williams, medwireNews Reporter
medwireNews: Progression-free survival findings from two phase 3 clinical trials support the use of targeted therapies in combination with transarterial chemoembolisation for the treatment of patients with unresectable, nonmetastatic hepatocellular carcinoma.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © Crystal light / stock.adobe.com
